Rapid risk assessment: Multiple reports of locally-acquired malaria infections in the EU
In the context of five recent events of local malaria transmission in the EU, we assess the risk of malaria spread in the EU.
Rapid Risk Assessment: Clusters of autochthonous chikungunya cases in Italy
Two related clusters involving autochthonous transmission of chikungunya virus have been detected in the cities of Anzio and Rome. This rapid risk assessment provides detailed event background information and assesses the threat for the European Union.
Rapid Risk Assessment: Hurricane Irma: risk of communicable diseases in the affected countries
On 29 August 2017, the US National Hurricane Center (NHC) reported the formation of the Hurricane Irma in the Atlantic Ocean. On 31 August 2017, Hurricane Irma was classified as category 3 on the Saffir-Simpson hurricane wind scale ranging from 1 to 5, however in the days that followed it gained in intensity.
Expert opinion on rotavirus vaccination in infancy
ECDC has published an Expert Opinion on rotavirus vaccination in infancy. The paper provides EU/EEA Member States with relevant scientific information on burden of rotavirus disease, vaccine effectiveness and safety, and cost-effectiveness studies to support the decision-making process on the possible introduction of routine vaccination of children against rotavirus gastroenteritis.
Rapid Risk Assessment: Cluster of autochthonous chikungunya cases in France
This rapid risk assessment has been produced In the context of a cluster of four confirmed cases and one probable locally-acquired case of chikungunya in Var department, in southern France.
Zika virus and safety of substances of human origin: a guide for preparedness activities in Europe – first update
This first update of the original guide was prompted by the evolution of the Zika virus epidemic, a new classification system for countries/areas, and recent scientific developments.
Expert panel reviews neuraminidase inhibitors for the prevention and treatment of influenza
An ECDC expert opinion concludes that there is clear evidence supporting the use of neuraminidase inhibitors in the treatment and prevention of influenza. Moreover, the current recommendations in European countries on the use of the neuraminidase inhibitors oseltamivir and zanamivir are appropriate and should be applied by prescribing physicians.
Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza - review of recent systematic reviews and meta-analyses
This ECDC expert opinion confirms earlier assessments by ECDC and national authorities that there is no significant new evidence to support any changes to the approved indications and recommended use of neuraminidase inhibitors (NAIs) in EU/EEA Member States.
Rapid Risk Assessment: Public health risks related to communicable diseases during the Hajj 2017, Saudi Arabia, 30 August – 4 September 2017
This document assesses the potential risk of outbreaks and transmission of communicable diseases during the Hajj taking place between 30 August and 4 September 2017.
Rapid risk assessment: Cyclospora infections in European travellers returning from Mexico - 21 July 2017
Assessment of the prolonged outbreak of Cyclospora infections in Mexico which has been affecting European travellers for at least three consecutive years.